Pharmacology, Toxicology and Pharmaceutical Science
Active Metabolite
19%
Amikacin
37%
Antibiotic Therapy
19%
Antibiotics
51%
Antimicrobial Resistance
19%
Antimycobacterial Agent
12%
Aspergillus
19%
Bedaquiline
32%
Bloodstream Infection
25%
Clarithromycin
15%
Clinical Trial
22%
Clofazimine
24%
Cohort Study
28%
Comorbidity
19%
Crystal Violet
9%
Cystic Fibrosis
9%
Delamanid
38%
Diseases
19%
Drug Development
24%
Drug Resistant Tuberculosis
21%
Effusion
19%
Ethambutol
24%
Human Study
19%
Hyperthermia
16%
Imipenem
19%
Incubation Time
9%
Infection
100%
Infectious Agent
12%
Isoniazid Plus Pyrazinamide Plus Rifampicin
11%
Linezolid
38%
Lung Disease
12%
Lung Infection
28%
Macrolide
12%
Monotherapy
19%
Mouse Model
11%
Mycobacterium abscessus
57%
Mycobacterium marinum
19%
Mycobacterium Tuberculosis
36%
Pharmacodynamics
19%
Pharmacokinetics
24%
Predictive Modeling
19%
Pretomanid
24%
Prevalence
12%
Quinoline Derivative
19%
Rifamycin
19%
Streptococcus pneumonia
14%
Tetracycline
19%
Thioridazine
11%
Tuberculostatic Agent
24%
Verapamil
11%
Medicine and Dentistry
Adverse Event
9%
Antibiotic Therapy
19%
Aspergillus
19%
Blood Culture
12%
Bloodstream Infection
25%
Cellulitis
9%
Charlson Comorbidity Index
16%
Clinical Trial
19%
Clinician
9%
Clofazimine
5%
Comorbidity
19%
Confocal Microscopy
19%
COVID-19
43%
Diabetes
9%
Drug Activity
19%
Drug Resistant Tuberculosis
9%
Edema
9%
Emergency Department
38%
Hyperthermia
16%
Hypothermia
6%
Immunosuppressive Treatment
9%
In Vitro
27%
Infection
28%
Intensive Care Unit
19%
Intermittent Pneumatic Compression
9%
Internal Medicine
9%
Likert Scale
9%
Lower Leg
9%
Lung Infection
19%
Medicine
9%
Microbiological Examination
9%
Mycobacterium abscessus
19%
Mycobacterium Chimaera
19%
Odds Ratio
18%
Papule
9%
Patient Care
9%
Patient Monitoring
9%
Physical Disease by Body Function
9%
Pneumococcal Pneumonia
12%
Pseudallescheriasis
19%
Public Health
19%
Retrospective Cohort Study
22%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Streptococcus pneumonia
12%
Thrombosis
9%
Vein Insufficiency
9%
Virus Infectivity
19%
Virus Shedding
19%
Vital Sign
6%
Voriconazole
9%
Immunology and Microbiology
Antibiotic Sensitivity
20%
Biofilm
19%
Comorbidity
19%
Confocal Microscopy
19%
COVID-19
19%
Drug Activity
38%
Escherichia coli
9%
Minimum Inhibitory Concentration
11%
Morphotype
5%
Mycobacterium abscessus
38%
Mycobacterium Chimaera
19%
Pseudomonas aeruginosa
6%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Staphylococcus Aureus
6%
Viral Shedding
19%
Virus Infectivity
19%
